|249.57||+0.6300||+0.25%||Vol 1.08M||1Y Perf 14.14%|
|Apr 13th, 2021 15:15 DELAYED|
|- -%||- -|
|Target Price||259.29||Analyst Rating||Moderate Buy 2.11|
|Potential %||3.94||Finscreener Ranking||★★ 46.98|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★ 51.17|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★+ 58.38|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||★★+ 44.32|
|Market Cap||143.70B||Earnings Rating||Sell|
|Price Range Ratio 52W %||59.16||Earnings Date||27th Apr 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||27th Apr 2021|
|Estimated EPS Next Report||4.03|
|EPS Growth Next 5 Years %||8.40|
|Avg. Weekly Volume||1.48M|
|Avg. Monthly Volume||2.82M|
|Avg. Quarterly Volume||2.67M|
Amgen Inc. (NASDAQ: AMGN) stock closed at 248.94 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 1.72M shares and market capitalization of 143.70B. Is a component of S&P 500, NASDAQ 100, Dow Jones 30, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 24300 people. Amgen Inc. CEO is Robert A. Bradway.
The one-year performance of Amgen Inc. stock is 14.14%, while year-to-date (YTD) performance is 8.27%. AMGN stock has a five-year performance of 57.46%. Its 52-week range is between 210.28 and 276.69, which gives AMGN stock a 52-week price range ratio of 59.16%
Amgen Inc. currently has a PE ratio of 20.00, a price-to-book (PB) ratio of 15.11, a price-to-sale (PS) ratio of 7.44, a price to cashflow ratio of 13.90, a PEG ratio of 2.32, a ROA of 11.35%, a ROC of 19.06% and a ROE of 72.86%. The company’s profit margin is 28.19%, its EBITDA margin is 51.10%, and its revenue ttm is $19.26 Billion , which makes it $33.45 revenue per share.
Of the last four earnings reports from Amgen Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $4.03 for the next earnings report. Amgen Inc.’s next earnings report date is 27th Apr 2021.
The consensus rating of Wall Street analysts for Amgen Inc. is Moderate Buy (2.11), with a target price of $259.29, which is +3.94% compared to the current price. The earnings rating for Amgen Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Amgen Inc. has a dividend yield of 2.83% with a dividend per share of $7.04 and a payout ratio of 50.00%.
Amgen Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 7.26, ATR14 : 6.00, CCI20 : 42.49, Chaikin Money Flow : 0.27, MACD : -1.26, Money Flow Index : 42.64, ROC : 1.41, RSI : 45.95, STOCH (14,3) : 40.09, STOCH RSI : 1.00, UO : 53.86, Williams %R : -59.91), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Amgen Inc. in the last 12-months were: David M. Reese (Option Excercise at a value of $125 787), Jonathan P. Graham (Sold 11 110 shares of value $2 627 625 ), Robert A. Bradway (Option Excercise at a value of $11 440 325), Robert Sanders Williams (Sold 1 850 shares of value $443 286 ), Ronald D. Sugar (Option Excercise at a value of $761 820), Ronald D. Sugar (Sold 13 000 shares of value $3 089 860 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.